Table 2.

The association between CS use for irAEs and cancer prognosis.

Authors	Year	Original Disease	No. of Cases (CS-Naïve: Needed CS)	Impact of CS on Response Rate or Survival
Horvat et al. [75]	2015	melanoma	195:103	Systemic CS was not associated with OS or TTF
Weber et al. [76]	2017	melanoma	462:114	ORR was 31.8% in CS-naïve group and 29.8% in CS-needed group (p = 0.736); median duration of response was 22.0 months in CS-naïve group and not reached in CS-needed group
Skribek et al. [77]	2020	lung cancer	104:31	OS was 14.43 months in CS-naïve group and not reached in CS-needed group (p = 0.38)

CS, corticosteroid; OS, overall survival; TTF, time to treatment failure; ORR, overall response rate.